SRT1720 HCl

Catalog No.S1129

SRT1720 HCl Chemical Structure

Molecular Weight(MW): 506.02

SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.

Size Price Stock Quantity  
In DMSO USD 238 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • EMBO J 2013 32, 791-804. SRT1720 HCl purchased from Selleck.

    PAI-1 expression in HUVECs treated with drugs as indicated.(D) senescent HUVECs were treated with SRT1720, culturing for 24, 48 hours. PAI-1 mRNA and protein (E) levels were analyzed using real-time RT–PCR and Western blotting, respectively. The RNA and protein levels were normalized to the internal control β-actin. Data are presented as the mean±SEM of three independent experiments. *P < 0.05 vs. corresponding control. **P < 0.01 vs. corresponding control ***P < 0.001 vs. corresponding control.

    Aging Cell 2014 13(5), 890-9. SRT1720 HCl purchased from Selleck.

  • Sirt1 deacetylase activity is essential for IRF9-mediated ischemic injury. The effects of SRT1720 on Sirt1 deacetylase activity in IRF9-KO and IRF9-TG mice, respectively. *p < 0.05 versus DMSO controls. n = 5.

    J Neurosci 2014 34(36), 11897-912. SRT1720 HCl purchased from Selleck.

    C2C12 myoblasts were transfected with si-CON and si-NDUFV1 for 24 h and then further differentiated into myotubes for 4 days in the absence or presence of pyruvate (25 mM), SRT1720 (2 uM), or resveratrol (Resv; 25 uM). Myogenesis was monitored using MyHC immunofluorescence and DAPI.

    J Biol Chem 2014 289(29), 20012-25. SRT1720 HCl purchased from Selleck.

  • J Biol Chem 2012 287, 19304-19314. SRT1720 HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Biological Activity

Description SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.
Targets
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  M{D1NWZ2dmO2aX;uJGF{e2G7 MlfUOOKh|ryP NGjFVVY{OMLibXnu NYrMXlFuTE2VTx?= NILBNZdqdmS3Y3XzJIFkfXSnIGPJVnQyKGGldHn2ZZRqd28EoB?= MYGyOlI2PDFyNB?=
MC3T3-E1 MVTGeY5kfGmxbjDBd5NigQ>? MVKxNEDDvU4EoB?= NFvuOIgyKGh? MVny[YR2[2W|IITo[UBVT0ZvzsKtd5RqdXWuYYTl[EBXTUeIIILlcIVie2ViaX6g[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5mesLi M4XoOVI3OTN4OUe4
MC3T3-E1 MVrGeY5kfGmxbjDBd5NigQ>? M3e3OFExKML3TdMg MmHqNVIhcA>? M2OzOZJm\HWlZYOgeIhmKF[HR1[gcXJPSSCneIDy[ZN{cW:wIHzleoVteyC|dHnteYxifGWmIHL5JHRITi4Qsh?= MVKyOlE{Pjl5OB?=
MC3T3-E1 NVjJWZc6TnWwY4Tpc44hSXO|YYm= NXfqNVhyOjBizszN NYXHd2IyOSCq NU\SephFe3WycILld5NmeyC2aHWgWGdHNc7{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIIC0OE9xPDJiTVHQJItqdmG|ZTDvdkBUSVCNL1rOTy=> NYHsd|Z6OjZzM{[5O|g>
WE-68 MnjZRZBweHSxc3nzJGF{e2G7 MlPrNE0zPCEQvF2= NFTNfFAzPCCq NF3MOmdqdmS3Y3XzJINmdGxiZHXheIghcW5iZH;z[UBl\XCnbnTlcpRtgQ>? NWHRblJDOjZyNUW4NFU>
SK-ES-1 M1ni[2Fxd3C2b4Ppd{BCe3OjeR?= NH;mdYwxNTFyIN88US=> NEP1dXEzPCCq Mke0bY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk> M4jLeFI3ODV3OEC1
SK-N-MC  M2jXNGFxd3C2b4Ppd{BCe3OjeR?= M3zZUFAuOi53IN88US=> M4XCUlI1KGh? NEPFbW1qdmS3Y3XzJINmdGxiZHXheIghcW5iZH;z[UBl\XCnbnTlcpRtgQ>? NEC4bnIzPjB3NUiwOS=>
WE-68 NVS3bVRuTnWwY4Tpc44hSXO|YYm= M{TIZlIxKM7:TR?= NYD3NHU2OC1{NDDo M3nr[oFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? MV[yOlA2PThyNR?=
SK-ES-1 MWXGeY5kfGmxbjDBd5NigQ>? NUW0OoFiOTBizszN NX\vZVRNOC1{NDDo M3zVSoFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? NHXBcGEzPjB3NUiwOS=>
SK-N-MC  M4n1UGZ2dmO2aX;uJGF{e2G7 MUmzJO69VQ>? NWeyfnhCOC1{NDDo M{XISIFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? M1PpcFI3ODV3OEC1
NRK-49F MkXCSpVv[3Srb36gRZN{[Xl? Mkn0NQKBmzMEoN88US=> NGjTc2k{PiCq NWTleFhHcW6lcnXhd4V{KGW6cILld5Nqd25ib3[g{tEuW02DIHHu[EBncWK{b37lZ5RqdiCmb4PlJIRmeGWwZHXueIx6 MmO3NlYxOjJyMEO=
NRK-49F M2LyS2Z2dmO2aX;uJGF{e2G7 M4nYdFDjiJN{wrFOwG0> NIPiemU{PiCq MoXR[Y5p[W6lZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGVITlJiYX7kJHBFT0[UzsNCpC=> M17velI3ODJ{MECz
NRK-49F Mn7xSpVv[3Srb36gRZN{[Xl? M4q1cVDjiJN{wrFOwG0> NH7zfW4{PiCq NGTQV|JmdmijbnPld{BUXEGWMzDwbI9{eGixconsZZRqd25? MnzZNlYxOjJyMEO=
RAW264.7 NYP0OGJRTnWwY4Tpc44hSXO|YYm= MYKxJO69VQ>? Ml\VOkBp M1THWZVxemWpdXzheIV{KHSqZTDy[YR2[2WmIGPJVnQyKHC{b4TlbY4hd3JibWLORUBt\X[nbIOgZpkhcGmpaDDncJVkd3On NFq0RmYzPTd7M{m5OS=>
MCF10A Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnryNE0zOCEQvF2= MmD1NlQhcA>? MXny[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MmX0NlU1OTF|NU[=
MCF-7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGwMVIxKM7:TR?= MlK3NlQhcA>? MYny[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MnTaNlU1OTF|NU[=
T47D NEnzT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuwMVIxKM7:TR?= MnnGNlQhcA>? MljPdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXrZS3Q5OjV2MUGzOVY>
SKBR3 NXTuUI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDQNE0zOCEQvF2= Mn[5NlQhcA>? M1HESJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MlPxNlU1OTF|NU[=
MDA-MB-231 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLvTVA5OC1{MDFOwG0> MorMNlQhcA>? MojOdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NYH5eVhXOjV2MUGzOVY>
SUM149 Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSwMVIxKM7:TR?= Mn3ENlQhcA>? NYjtcXhEemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NHzNT3gzPTRzMUO1Oi=>
HS578T NF;TPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISzOVcxNTJyIN88US=> NVzmemRsOjRiaB?= NHHoV5lz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NEjHe|MzPTRzMUO1Oi=>
BT20 NGHRSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nXdlAuOjBizszN M{j6Z|I1KGh? Mmf4doVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M2rhR|I2PDFzM{W2
A459 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjENE0zOCEQvF2= MUCyOEBp NITnV3Jz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NUXqfHl2OjV2MUGzOVY>
HCT116 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLwdIExNTJyIN88US=> NVnRc4F6OjRiaB?= NWTUSppKemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M2nNZlI2PDFzM{W2
Neu NXnCfFBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrBNE0zOCEQvF2= M2XOPVI1KGh? NYTndpdSemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MmjuNlU1OTF|NU[=
MDA-MB-231 Mn63SpVv[3Srb36gRZN{[Xl? MonCOUDPxE1? M2T5S|ghcA>? MlH5bY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiYXPp[IlkKH[nc3njeYxieiCxcnfhcoVtdGW| MX2yOVQyOTN3Nh?=
MDA-MB-231 M{fae2Z2dmO2aX;uJGF{e2G7 M3zCZ|Uh|ryP NI\BUFIyPiCq MnzjbY5lfWOnczDsfZNwe2:vYXygcYVu[nKjbnWgdIVzdWWjYnnsbZpifGmxbh?= MYCyOVQyOTN3Nh?=
MC3T3-E1 MV\GeY5kfGmxbjDBd5NigQ>? MUOxNEDPxE1? NIHXZ|U3OCCvaX9CpC=> NYfM[WY1e3WycILld5NmeyC2aHWgSmdHNTJvc4TpcZVt[XSnZDDvd5Rmd3C{b4Tl[4VzcW5icnXs[YF{\Q>? NIG4PYwzPTJ7MEC5OS=>
MC3T3-E1 MUfGeY5kfGmxbjDBd5NigQ>? MlvMNVAh|ryP NYPtRotxPjBibXnuxsA> NUDTT3lQ[XS2ZX71ZZRmeyC2aHWgSmdHNTJvaX7keYNm\CCxc4Tlc5Bzd3SnZ3XybY4hdVKQQTDlfJBz\XO|aX;u MoDoNlUzQTByOUW=
MC3T3-E1 MWjGeY5kfGmxbjDBd5NigQ>? NFnl[pYyOCEQvF2= MmnhOlAhdWmwwrC= MlvUZZR1\W63YYTld{B1cGViRlfGMVIucW6mdXPl[EBwe3Snb4Dyc5Rm\2W{aX6gcXJPSSCneIDy[ZN{cW:w M1r6[VI2OjlyMEm1
MC3T3-E1 M2H0SmZ2dmO2aX;uJGF{e2G7 NWXadXpuOTBizszN M3TSeVYxKG2rbtMg Mlztd5VxeHKnc4Pld{B1cGViQl3QMVQue3SrbYXsZZRm\CCYRVfGJJJmdGWjc3W= NFLHcY0zPDR|NUS0OC=>
MC3T3-E1 NYXyOIg2TnWwY4Tpc44hSXO|YYm= MUSxNEDPxE1? MorLOlAhdWmwwrC= NUK3S3k5e3WycILld5NmeyC2aHWgVGdHOs7zLYP0bY12dGG2ZXSgU3BIKHKnbHXhd4U> MkW5NlQ{OzN|M{[=
MC3T3-E1 NYn1fVZrTnWwY4Tpc44hSXO|YYm= MoDBNVAh|ryP Mn36OlAhdWmwwrC= M2HxRpJm\HWlZYOgeIhmKFCJRkNOtU1{fGmvdXzheIVlKHCqb4PwbI9zgWyjdHnvckBw\iCyNESvdFQzKE2DUDDrbY5ie2V? NV;OTY5pOjR|M{OzN|Y>
MC3T3-E1 NV;CWVdRTnWwY4Tpc44hSXO|YYm= MX:xNEDPxE1? M1fUPVYxKG2rbtMg NFOzd5lifHSnboXheIV{KHSqZTDQS2Yz|rFvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBOTUtzL{KgZY5lKFKjZj2x MWSyOFM{OzN|Nh?=
RPE NGfKZmdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4fPSVUhyrWP NEO4coIyKGh? MWjheJRmdnWjdHXzJG9C|rJvaX7keYNm\CCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gQ>? MmL1NlQxOzZ7M{i=
9607 M4e1[mNmdGxiVnnhZoltcXS7IFHzd4F6 NH\vNlUyKM7:TR?= NUHBSWE2OzZiaB?= M2\LV4lv[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[2:vcHHy[YQhf2m2aDDt[YxifG:waX6gZYxwdmV? MVGyN|czPjl2OR?=
9607 NYfUXYNUTnWwY4Tpc44hSXO|YYm= NHP1ZYUyKM7:TR?= NXTmNHlHOzZiaB?= MonnbY5kemWjc3XzJHNKWlRzIHHu[EBl\WO{ZXHz[YQh[WOndInsZZRm\C2yNUOg[ZhxemW|c3nvci=> NGXTOoIzOzd{Nkm0PS=>
RPMI.8226 NWnGXpI3S2WubDDWbYFjcWyrdImgRZN{[Xl? Mk\lO{8yOCEQvF2= NVHuR4NpOjRiaB?= MX7k[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NYjPPW4{OjF7NUC3Nlg>
U266 NVT3[FV{S2WubDDWbYFjcWyrdImgRZN{[Xl? MmjyO{8yOCEQvF2= NYXyXnVKOjRiaB?= MlTH[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 M4K5VFIyQTVyN{K4
MM.1S NFH5fGVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXq3M|ExKM7:TR?= Mk[4NlQhcA>? NHTPTXll\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MljHNlE6PTB5Mki=
KMS12 NFzrSZRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYXDVYx4Py9zMDFOwG0> MnfkNlQhcA>? M{fQd4Rm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> MVGyNVk2ODd{OB?=
LR5 MkO0R4VtdCCYaXHibYxqfHliQYPzZZk> NEDYNYg4NzFyIN88US=> M3\UNlI1KGh? MX3k[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MmfvNlE6PTB5Mki=
MM.1R NYn4dW9SS2WubDDWbYFjcWyrdImgRZN{[Xl? NWHPdo1xPy9zMDFOwG0> MV[yOEBp M4XvcYRm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> NGP5SXMzOTl3MEeyPC=>
Ina6 M1rZ[mNmdGxiVnnhZoltcXS7IFHzd4F6 NFrIPG84NzFyIN88US=> NXT2RXhPOjRiaB?= MoTJ[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MkXlNlE6PTB5Mki=
RPMI-8226 NVHtPG9bSXCxcITvd4l{KEG|c3H5 NH2xdlY4NzFyIN88US=> M{H2clI1KGh? MWXpcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5idHjlJGFvdmW6aX6gWkswWEokiKNCpIFxd3C2b4Ppdy=> MUmyNVk2ODd{OB?=
MM.1R  M{DFOWFxd3C2b4Ppd{BCe3OjeR?= M2TBUFcwOTBizszN NW\EfJdUOjRiaB?= MoDBbY5lfWOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIITo[UBCdm6neHnuJHYsN1CL4pkSxsBieG:ydH;zbZM> NVrBXnN1OjF7NUC3Nlg>
H411EC3 MXvGeY5kfGmxbjDBd5NigQ>? NH7zW4s2OC9zMECgcm0> MUS2JIg> NEW3RVdqdmO{ZXHz[ZMhW0mUVEGgZYN1cX[rdImgbY4hfGinIIDy[ZNmdmOnIH;mJHRUSSxiUFXQR2sh[WO2aY\peJktKG2UTlGgcIV3\Wy|IH;mJHBkczFiYX7kJHBo[zIQsTygZY5lKGWuZY\heIlv\yCpbIXjc5NmKHC{b3T1Z5Rqd25? MUSyNVIyOjB7Nh?=
hepatocytes NEjVUm5HfW6ldHnvckBCe3OjeR?= M2m3d|ExKG6P Ml7wOkBp NUDtc3ZHcW6lcnXhd4V{KFOLUmSxJIFkfGm4aYT5JIlvKHSqZTDwdoV{\W6lZTDv[kBVW0FuIGDFVGNMKGGldHn2bZR6NCCvUl7BJIxmfmWuczDv[kBR[2tzIHHu[EBR\2NzzsGsJIFv\CCnbHX2ZZRqdmdiZ3z1Z49{\SCycn;keYN1cW:w NYL6W5NMOjF{MUKwPVY>
hepatocytes MYnGeY5kfGmxbjDBd5NigQ>? MY[xNEBvVQ>? MVG2JIg> M2\Wdolv[3KnYYPld{BJdWelctMgZY5lyqCDY3RCpIdmdmViZYjwdoV{e2mxbh?= MlHWNlEzOTJyOU[=

... Click to View More Cell Line Experimental Data

In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol

Kinase Assay:[1]
+ Expand

SIRT1 fluorescence polarization assay:

In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.
Cell Research:[2]
+ Expand
  • Cell lines: Human vascular endothelial cells (HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2 hours
  • Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Chase-SCID mice with MM.1S cells
  • Formulation: 20% PEG400/0.5% Tween80/79.5% deionized water
  • Dosages: 200 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (75.09 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 506.02
Formula

C25H23N7OS.HCl

CAS No. 1001645-58-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we prepare Srt1720 for in vivo mouse studies?

  • Answer:

    SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.

Sirtuin Signaling Pathway Map

Related Sirtuin Products0

Tags: buy SRT1720 HCl | SRT1720 HCl supplier | purchase SRT1720 HCl | SRT1720 HCl cost | SRT1720 HCl manufacturer | order SRT1720 HCl | SRT1720 HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID